Microfluidic Mixing LNP Patents: Who Leads, Where the Gaps Are 2026
- Half the field sits with a handful of filers. the top 5 assignees hold 78 of 156 records in scope (50.0%), and the top 10 hold 108 (69.2%).
- Filing has plateaued, not accelerated. activity peaked in 2024 at 15 records after a flat-to-declining stretch through the 2022 midpoint (8 records).
- Mixing hardware dominates the claim space. B01F (mixing & stirring) appears in 66.0% of records, more than triple the share of A61K medicinal-preparation claims.
Filing growth compares 2021 (14 records) with 2024 (15) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 156 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 156 published records filed between 2015 and mid-2026 that describe microfluidic mixing methods and devices used to formulate lipid nanoparticles (LNPs) — staggered herringbone mixers, T-junction geometries, and related chip-based mixing architectures, together with the manufacturing problems that follow from them: mixing time control, particle size distribution, encapsulation efficiency, fouling resistance, and parallelization for scale-up. The scope is drawn narrowly around mixing hardware and process claims rather than lipid chemistry itself, which is why medicinal-preparation classifications (A61K) appear in under a fifth of records even though every filing here ultimately supports LNP-based drug or vaccine delivery.
Publication data lags actual filing by roughly 18 months, so the most recent year in any trend undercounts real activity — 2026 figures in particular should be read as a floor, not a ceiling.
Filing trend and technology composition
Two views of the same 156 records: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
A plateau after a 2024 peak
Filings ran at 11 in 2017 and reached a peak of 15 in 2024, with the 2022 midpoint at 8 — a pattern of flat-to-declining growth rather than sustained acceleration. The 2026 figure is partial because of publication lag and should not be read as a drop-off.
Mixing hardware, not formulation chemistry, is where claims concentrate
B01F (mixing and stirring) touches 66.0% of the 156 records, with B01L (lab apparatus) and A61K (medicinal preparations) well behind at 25.6% and 19.2%. Because records can carry multiple IPC classes, these shares add up past 100% — the pattern to read is which subclasses cluster together, not a single dominant category.
Shares are the percentage of the 156 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microfluidic Mixing for Lipid Nanoparticle Manufacturing with Eureka
This page is one run against one query. Ask Eureka your own question about microfluidic mixing for lipid nanoparticle manufacturing and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this corpus
Fouling resistant microfluidic mixing device for robust manufacturing of nanoparticles (WO2024243053A1)
A microfluidic component built around at least one microchannel with a tethered liquid perfluorocarbon (TLP) coating on its internal surface, sized roughly 10 to 1000 micrometres across, paired with a method of operating a system that uses this component to formulate lipid nanoparticles.Filed by The Trustees of the University of Pennsylvania, published 2024-11-28.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2011140627A1 | Nucleic acid-containing lipid particles and related methods | 298 |
| 2 | US10076730B2 | Bifurcating mixers and methods of their use and manufacture | 38 |
| 3 | US20190105619A1 | Secure portable, on-demand, microfluidic mixing and dispensing device | 36 |
| 4 | WO2017117647A1 | Bifurcating mixers and methods of their use and manufacture | 36 |
| 5 | WO2017180660A1 | Secure portable, on-demand, microfluidic mixing and dispensing device | 30 |
| 6 | US10835878B2 | Bifurcating mixers and methods of their use and manufacture | 19 |
| 7 | WO2005094976A1 | Microfluidic mixing | 19 |
| 8 | US20170082551A1 | Mobile microfluidic determination of analytes | 14 |
| 9 | WO2008039209A1 | Microfluidic serial dilution circuit | 14 |
| 10 | WO2006105616A1 | Method for microfluidic mixing and mixing device | 13 |
Citation counts inside a searched corpus favour older filings that have had more time to accumulate references — treat them as a signal of influence on the field, not a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three patterns worth acting on before drafting a new claim set in this space.
Half the field is already claimed by five filers
The leader alone holds 30 records, with the fifth-place assignee at 9. That gap between first and fifth suggests one dominant program surrounded by several mid-sized portfolios rather than an even spread — worth checking directly before assuming open space in core mixer geometries.
Growth has stalled since the 2022 midpoint
Filings were at 8 by 2022 and peaked at 15 two years later — a pattern more consistent with a maturing claim space than with an emerging one still attracting new entrants. New filers should expect to design around existing hardware claims rather than stake out fresh mixer architectures.
Hardware claims outnumber formulation claims by more than 3 to 1
B01F mixing and stirring classifications touch two in three records, while A61K medicinal-preparation classifications touch fewer than one in five. That imbalance points to where the competitive pressure actually sits: mixer geometry and flow control, not lipid formulation chemistry.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microfluidic mixing for lipid nanoparticle manufacturing, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| The University of British Columbia | WILD ANDRE | 1 |
| The University of British Columbia | WALKER DAVID | 1 |
| The University of British Columbia | TAYLOR JAMES | 1 |
| The University of British Columbia | MALCOM STUART | 1 |
| The University of British Columbia | LEUNG ALEX | 1 |
| The University of British Columbia | HUFT JENS | 1 |
| The University of British Columbia | HANSEN CARL LARS GENGHIS | 1 |
| The University of British Columbia | HAFEZ ISMAIL | 1 |
Only 10 co-assignee pairs appear across the dataset, and the strongest pairings link a single university to individual named inventors rather than to other companies — this field is being built through solo filings, not joint ventures.
Who holds the claim space, and where it thins out
A ranking of 81 companies, drawn from the full assignee list the dataset returns for this search — not a top-50 or top-100 cut.
One filer well ahead of the field
The leading assignee holds 30 of the 156 records in scope, more than three times the fifth-place count of 9. Any freedom-to-operate check in core staggered-herringbone or T-junction mixer geometry should start with this portfolio.
A cluster of mid-sized programs
Places two through five hold a combined portfolio that trails the leader but still represents sustained, multi-filing programs rather than one-off applications — these are the assignees most likely to contest a new entrant's claims on mixing time or particle size distribution control.
Most of the 81 ranked companies file once or twice
Beyond the top 10, the ranking thins quickly into single- and double-filing entrants — universities, contract manufacturers and startups testing specific mixer variants. This tail is where narrow, defensible claims on fouling resistance or parallelization are most likely to still be available.
| Assignee | Recent year | YoY |
|---|---|---|
| The University of British Columbia | 0 | — |
| Altopa Inc. | 0 | — |
| National Research Council of Canada | 0 | — |
| Avectas | 0 | — |
| Natures Toolbox Inc. | 0 | — |
| GlaxoSmithKline Biologicals SA | 0 | — |
| Gyros Patent AB | 0 | — |
| BELLEROPHON BCM LLC | 0 | — |
Where to take this analysis
The landscape points to specific next steps depending on whether the goal is freedom-to-operate, whitespace filing, or portfolio benchmarking.
Run a freedom-to-operate check against the leading portfolio
With one assignee holding 30 of 156 records, any new mixer geometry or fouling-resistance claim should be checked against that portfolio specifically before drafting.
Explore assignee portfolios in EurekaTest claim language in the under-claimed branches
Parallelization, inline particle size feedback and fouling-resistant coatings show thinner density than core mixer geometry — a good starting point for drafting narrow, defensible claims.
Search prior art in EurekaTrack filing momentum by assignee, not just by year
Aggregate filings have plateaued since 2022, but that masks which individual programs are still active versus dormant — worth checking assignee-level trends before assuming the field has cooled uniformly.
Monitor assignee activity in EurekaCommon questions about this landscape
This dataset identifies 156 published records filed between 2015 and mid-2026 that describe microfluidic mixing methods or devices for lipid nanoparticle formulation, using a search built around staggered herringbone mixers, T-junction geometries, and related manufacturing terms like mixing time, particle size distribution and encapsulation efficiency. The true figure is somewhat higher because publication lags filing by roughly 18 months, so 2025 and 2026 filings are undercounted. Patent families are the more reliable unit than raw document counts, since a single invention can generate several related filings across jurisdictions.
The field is concentrated: the top 5 assignees together hold 78 of the 156 records in scope, or 50.0%, and the top 10 hold 108, or 69.2%. The single leading assignee holds 30 records, well ahead of the fifth-place holder at 9. Beyond the top 10, the ranking — which covers 81 companies in total — thins into a long tail of single- and double-filing universities, startups and contract manufacturers.
Filing volume has plateaued rather than grown. Records ran at 11 in 2017, sat at 8 by the 2022 midpoint, and peaked at 15 in 2024 — a pattern more consistent with a maturing, already-claimed space than with an emerging one still drawing new entrants. The apparent drop in 2026 is largely a publication-lag artefact rather than a real decline, but the multi-year trend before that shows flat-to-declining growth.
WO2024243053A1, assigned to The Trustees of the University of Pennsylvania and published November 2024, claims a microfluidic component with a tethered liquid perfluorocarbon (TLP) coating on the inner surface of a microchannel roughly 10 to 1000 micrometres in cross-section, plus a method of using that component to formulate lipid nanoparticles. The core protection is the fouling-resistant coating chemistry applied to a mixing channel, not mixer geometry itself. Anyone designing a new mixing chip for LNP manufacturing with a similar anti-fouling surface treatment should review this filing's claim scope directly.
The IPC composition shows heavy density in B01F mixing and stirring (66.0% of records) and B01L lab apparatus (25.6%), but much thinner coverage in areas like G16H healthcare informatics (7.1%) and A61J medicine containers (9.0%). Sub-areas such as parallelized multi-chip mixing arrays, inline particle size feedback control, and fouling-resistant coatings outside the TLP approach show less claim density than core mixer geometry. These are reasonable starting points for narrow, defensible new filings, though each should be checked against the specific leading portfolios first.
Research Microfluidic Mixing for Lipid Nanoparticle Manufacturing in depth with Eureka
Go past this page: query the whole microfluidic mixing for lipid nanoparticle manufacturing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.